Vaxcyte (NASDAQ: PCVX) nets $600.2M in underwritten stock sale

Rhea-AI Filing Summary

Vaxcyte, Inc. entered into an underwriting agreement to issue and sell 11,000,000 shares of common stock at $50.00 per share to the public, with underwriters purchasing at $47.50 per share. The company granted underwriters a 30-day option to buy up to 1,650,000 additional shares, which they exercised in full. Including this option, Vaxcyte expects net proceeds of approximately $600.2 million after underwriting discounts, commissions and estimated expenses. The offering, made under an effective Form S-3 shelf registration, closed on February 2, 2026 and was led by a syndicate of major investment banks.

Insights

Equity capital markets analyst

Vaxcyte completes large underwritten equity raise, boosting cash but adding dilution.

Vaxcyte completed an underwritten public offering of 11,000,000 common shares at $50.00 per share, with underwriters paying $47.50. A 30-day option for up to 1,650,000 additional shares was granted and later exercised in full, indicating full take-up by the syndicate.

The transaction generated approximately $600.2 million in net proceeds, after underwriting discounts, commissions and estimated expenses. As all shares were sold by the company, this represents a primary capital raise rather than a resale, implying added cash for corporate purposes alongside incremental equity dilution for existing holders.

The deal was conducted under an effective Form S-3 shelf registration, with BofA Securities, Jefferies, Leerink Partners and Evercore acting as representatives of the underwriters. Future company filings may clarify how this new capital is allocated across development programs, operations, or other strategic uses.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001649094 0001649094 2026-01-29 2026-01-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 29, 2026

VAXCYTE, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-39323		46-4233385
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

825 Industrial Road
Suite 300
San Carlos, California		94070
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 837-0111

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		PCVX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events

Underwriting Agreement

On January 29, 2026, Vaxcyte, Inc. (“Vaxcyte”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Jefferies LLC, Leerink Partners LLC and Evercore Group L.L.C. as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 11,000,000 shares of its common stock, par value $0.001 per share, at a price to the public of $50.00 per share. Pursuant to the Underwriting Agreement, the Underwriters agreed to purchase the shares of common stock from Vaxcyte at a price of $47.50 per share. Vaxcyte also granted the Underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock from Vaxcyte. All of the shares in the Offering were sold by Vaxcyte.

On January 30, 2026, the Underwriters notified Vaxcyte of their intent to exercise their option to purchase the additional shares in full. The net proceeds to Vaxcyte from the Offering, including the exercise by the Underwriters of their 30-day option to purchase additional shares, was approximately $600.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Vaxcyte. The Offering closed on February 2, 2026.

The Offering was made pursuant to Vaxcyte’s effective registration statement on Form S-3 (Registration Statement No. 333-279735), as previously filed with the Securities and Exchange Commission and a related prospectus and prospectus supplement.

The Underwriting Agreement contains customary representations, warranties and covenants by Vaxcyte, customary conditions to closing, indemnification obligations of Vaxcyte and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, and were solely for the benefit of the parties to such agreement.

The Underwriting Agreement is filed as Exhibit 1.1 hereto. The foregoing descriptions of the terms of the Underwriting Agreement are qualified in their entirety by reference to such exhibits hereto. A copy of the opinion of Skadden, Arps, Slate, Meagher & Flom LLP relating to the legality of the issuance and sale of the securities in the Offering is attached as Exhibit 5.1 hereto.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
1.1		Underwriting Agreement, dated January 29, 2026
5.1		Opinion of Skadden, Arps, Slate, Meagher & Flom LLP
23.1		Consent of Skadden, Arps, Slate, Meagher & Flom LLP (contained in Exhibit 5.1)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

				VAXCYTE, INC.
Date: February 2, 2026				By:		/s/ Andrew Guggenhime
						Andrew Guggenhime
						President and Chief Financial Officer

FAQ

What did Vaxcyte (PCVX) announce in its latest 8-K filing?

Vaxcyte announced it entered into an underwriting agreement for a public offering of common stock. The company sold shares to investors through underwriters and received significant cash proceeds under an effective shelf registration statement on Form S-3.

How many Vaxcyte (PCVX) shares were included in the stock offering?

Vaxcyte’s offering covered 11,000,000 shares of common stock at a set public price. The company also granted underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock from Vaxcyte.

What price did Vaxcyte (PCVX) shares sell for in the offering?

The Vaxcyte shares were sold to the public at $50.00 per share. Underwriters purchased the shares from Vaxcyte at $47.50 per share, reflecting the standard underwriting discount between the public offering price and the company’s net sale price.

How much cash did Vaxcyte (PCVX) receive from the stock offering?

Vaxcyte reported approximately $600.2 million in net proceeds from the offering. This figure includes the underwriters’ full exercise of their 30-day option and is after underwriting discounts, commissions, and other estimated offering expenses payable by the company.

Did underwriters fully exercise their option in the Vaxcyte (PCVX) deal?

Yes. On January 30, 2026, underwriters notified Vaxcyte of their intent to exercise in full their 30-day option. That option allowed them to purchase up to an additional 1,650,000 shares of Vaxcyte common stock directly from the company.

When did the Vaxcyte (PCVX) stock offering close?

The Vaxcyte common stock offering closed on February 2, 2026. Closing followed execution of the underwriting agreement, pricing of the shares, and the underwriters’ decision to exercise their option to purchase additional shares from the company in full.

Under which registration statement was the Vaxcyte (PCVX) offering made?

The offering was conducted under Vaxcyte’s effective shelf registration statement on Form S-3, Registration Statement No. 333-279735. A related base prospectus and a specific prospectus supplement governed the terms of this common stock offering to investors.